EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer

Jaqueline B Schuch, Mariana R Botton, Angélica C De Baumont, Giovana Curzel, Nathan A Cadore, Cláudia Bordignon, Mahira L Rosa, Vitor F Vasconcellos, Lilian A R Barros, Cristiano P Souza, Williams F Barra, Daniela L C Louzeiro und 17 weitere

Frontiers in Pharmacology · 02.03.2026 · 17

DOI: 10.3389/fphar.2026.1736887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.03.2026. Verfasst von Jaqueline B Schuch und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Moinhos de Vento, Porto Alegre, Brazil. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pharmacogenomic (PGx) variants can influence drug efficacy and safety, yet their prevalence in Latin American populations with cancer is underexplored. Our aim is to characterize the frequency and phenotypic distribution of actionable pharmacogenes in Brazilian patients with metastatic prostate cancer (MPC) and Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer (BC).

Methods

This analysis included 452 patients (259 BC, 193 MPC) from a multicenter study across 19 Brazilian sites. Exome sequencing was performed, and PGx variants were analyzed using the Pharmacogenomics Clinical Annotation Tool (PharmCAT) following the Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines. Genotypes, star alleles, and predicted phenotypes were reported for 15 clinically relevant pharmacogenes.

Results

Actionable PGx phenotypes were detected in 99.33% of participants. The decreased-function ABCG2 rs2231142 T allele occurred at 8.96%, and the VKORC1 rs9923231 T allele at 32.63%. In SLCO1B1 , normal function predominated (63.11%), with 21.11% exhibiting decreased function. Normal metabolizer phenotypes were most frequent in CYP2C19 (45.35%), CYP2C9 (70.51%), and CYP3A4 (94.62%), whereas CYP2B6 was dominated by intermediate metabolizers (43.02%) and CYP3A5 by poor/intermediate metabolizers (93.79%). Normal diplotypes predominated in thiopurine-related genes ( NUDT15 : 92.92%; TPMT : 88.72%), although nonfunctional alleles were observed. In UGT1A1 , decreased-function alleles accounted for approximately 37% of participants. Clinically relevant DPYD and RYR1 variants were rare (<2.0%).

Conclusion

Nearly all Brazilian patients with cancer carried at least one actionable PGx variant, highlighting the potential impact of PGx-guided therapy in oncology. These results underscore the value of integrating pharmacogenomic strategies into clinical practice in Brazil.

Schlagwörter

Stichwörter der Autor:innen

breast neoplasmsexome sequencingpharmacogeneticspharmacogenomicsprostate neoplasms

Autor:innen und Institutionen

  • Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Universidade Federal do Rio Grande do Sul, Programa de Pós-Graduação em Genética e Biologia Molecular, Porto Alegre, Brazil.
  • Hospital Universitário Cassiano Antônio Moraes, Vitória, Brazil.
  • Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil.
  • Hospital de Câncer de Barretos, Barretos, Brazil.

Zitieren

APA

Schuch, J. B., Botton, M. R., De Baumont, A. C., Curzel, G., Cadore, N. A., Bordignon, C., Rosa, M. L., Vasconcellos, V. F., Barros, L. A. R., Souza, C. P., Barra, W. F., Louzeiro, D. L. C., Notari, A., de Menezes, J. J., Liedke, P. E. R., Bertollo, G. A., Gongora, A. B. L., Ascenco, H. G., Kowalski-Neto, E., …, & Rosa, D. D. (2026). Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1736887

Vancouver

Schuch JB, Botton MR, De Baumont AC, Curzel G, Cadore NA, Bordignon C, et al. Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1736887

BibTeX
@article{Schuch2026,
  author = {Schuch, Jaqueline B and Botton, Mariana R and De Baumont, Angélica C and Curzel, Giovana and Cadore, Nathan A and Bordignon, Cláudia and Rosa, Mahira L and Vasconcellos, Vitor F and Barros, Lilian A R and Souza, Cristiano P and Barra, Williams F and Louzeiro, Daniela L C and Notari, Alessandra and de Menezes, Juliana J and Liedke, Pedro E R and Bertollo, Gláucio A and Gongora, Aline B L and Ascenco, Henrique G and Kowalski-Neto, Eduardo and Oppermann, Christina P and Werutsky, Gustavo and Santos, Edilmar M and Brandão, Flavio S and Freitas-Junior, Ruffo and Nogueira-Rodrigues, Angélica and Mancini, André L C and Bessel, Marina and Macedo, Gabriel S and Rosa, Daniela D},
  title = {Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1736887}
}
Kostenlos starten →